On Wednesday, Goldman Sachs reaffirmed its Sell rating on Exelixis, Inc. (NASDAQ:), with a consistent price target of $18.00. The firm’s stance comes after the U.S. District Court in Delaware ruled in favor of Exelixis in a patent litigation case, ensuring protection against generic competition for its cancer drug cabozantinib until January 15, 2030, barring any successful appeals by MSN.
The court decision, announced on October 15, was seen as a significant win for Exelixis, as it dispels the immediate threat of generic entry that could have impacted the company’s revenue. Despite this favorable outcome, Goldman Sachs has chosen not to adjust its forecasts or investment recommendation, citing ongoing concerns over Exelixis’s revenue growth prospects post-2030.
Goldman Sachs acknowledges the potential for cabozantinib’s label expansion into neuroendocrine tumors (NET) with a Prescription Drug User Fee Act (PDUFA) date set for April 2025.
However, the firm remains cautious, especially given the recent clinical trial for metastatic castration-resistant prostate cancer (mCRPC), CONTACT-02, which did not meet its statistical significance endpoint.
The analyst notes that while Exelixis management is open to business development to bolster its portfolio, there is a lack of imminent events that could significantly improve the company’s outlook or act as catalysts.
The current pipeline, led by zanza and including several early-stage programs, does not provide enough near-term milestones to alter the firm’s cautious perspective. As a result, the Sell rating on Exelixis’s stock remains unchanged.
In other recent news, Exelixis’ Q2 revenues reached $637.2 million, largely driven by its leading product, cabozantinib, which contributed $437.6 million. Additionally, Exelixis has initiated a clinical development partnership with Merck to assess the efficacy of a new investigational cancer treatment. This collaboration involves a phase 3 trial for head and neck squamous cell carcinoma and multiple trials for renal cell carcinoma.
Analysts from firms such as Citi and H.C. Wainwright have reaffirmed their Buy rating on Exelixis shares, following the presentation of positive results from various Phase 3 trials. However, analysts from Stephens and UBS have maintained a neutral stance on Exelixis, citing potential intellectual property risks and a wait-and-see approach to assess market dynamics and legal challenges.
BMO Capital Markets and TD Cowen have maintained their positive outlook on Exelixis with price targets of $29.00 and $27.00 respectively. These are recent developments in the company’s journey.
InvestingPro Insights
While Goldman Sachs maintains a cautious stance on Exelixis, Inc. (NASDAQ:EXEL), recent data from InvestingPro paints a more nuanced picture of the company’s financial health and market performance. Despite concerns about long-term growth prospects, Exelixis has shown strong recent momentum, with InvestingPro data revealing a significant 25.22% price return over the last three months and a 12.07% return in just the past week.
InvestingPro Tips highlight that Exelixis holds more cash than debt on its balance sheet, indicating financial stability that could support future growth initiatives or weather potential challenges. Additionally, the company’s high shareholder yield suggests a commitment to returning value to investors, which may be attractive to some despite the absence of a dividend.
The company’s P/E ratio of 24.91, coupled with an adjusted P/E of 21.57 for the last twelve months as of Q2 2024, suggests that the stock may not be overvalued relative to its earnings, especially considering the expected net income growth this year. This growth expectation aligns with the company’s recent legal victory securing patent protection for cabozantinib until 2030.
For investors seeking a more comprehensive analysis, InvestingPro offers 12 additional tips that could provide deeper insights into Exelixis’s market position and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
